184 related articles for article (PubMed ID: 35956764)
1. MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases.
Gonçalves JPL; Bollwein C; Schlitter AM; Kriegsmann M; Jacob A; Weichert W; Schwamborn K
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956764
[TBL] [Abstract][Full Text] [Related]
2. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.
Casadonte R; Kriegsmann M; Perren A; Baretton G; Deininger SO; Kriegsmann K; Welsch T; Pilarsky C; Kriegsmann J
Proteomics Clin Appl; 2019 Jan; 13(1):e1800046. PubMed ID: 30548962
[TBL] [Abstract][Full Text] [Related]
3. MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.
Bollwein C; Gonҫalves JPL; Utpatel K; Weichert W; Schwamborn K
Molecules; 2022 May; 27(11):. PubMed ID: 35684402
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Analysis of Metastasis-Specific Biomarkers in Pancreatic Cancer: Galectin-1 Plays an Important Metastatic Role in Pancreatic Cancer.
Tung CL; Lin MW; Hu RY; Chien YC; Liao EC; Lin LH; Chung TW; Wei YS; Tsai YT; Chen HY; Chou HC; Kuo WH; Ko ML; Chang SJ; Lee YR; Chan HL
J Pharm Biomed Anal; 2020 Jul; 186():113300. PubMed ID: 32413824
[TBL] [Abstract][Full Text] [Related]
5. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.
Grüner BM; Hahne H; Mazur PK; Trajkovic-Arsic M; Maier S; Esposito I; Kalideris E; Michalski CW; Kleeff J; Rauser S; Schmid RM; Küster B; Walch A; Siveke JT
PLoS One; 2012; 7(6):e39424. PubMed ID: 22761793
[TBL] [Abstract][Full Text] [Related]
6. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
[TBL] [Abstract][Full Text] [Related]
7. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
[TBL] [Abstract][Full Text] [Related]
8. Classification of Pancreatic Ductal Adenocarcinoma Using MALDI Mass Spectrometry Imaging Combined with Neural Networks.
Kanter F; Lellmann J; Thiele H; Kalloger S; Schaeffer DF; Wellmann A; Klein O
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765644
[TBL] [Abstract][Full Text] [Related]
9. Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases.
Naidoo K; Jones R; Dmitrovic B; Wijesuriya N; Kocher H; Hart IR; Crnogorac-Jurcevic T
J Pathol; 2012 Apr; 226(5):756-63. PubMed ID: 22081483
[TBL] [Abstract][Full Text] [Related]
10. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma.
Shekouh AR; Thompson CC; Prime W; Campbell F; Hamlett J; Herrington CS; Lemoine NR; Crnogorac-Jurcevic T; Buechler MW; Friess H; Neoptolemos JP; Pennington SR; Costello E
Proteomics; 2003 Oct; 3(10):1988-2001. PubMed ID: 14625861
[TBL] [Abstract][Full Text] [Related]
11. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
12. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
[TBL] [Abstract][Full Text] [Related]
13. Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro-array.
Djidja MC; Claude E; Snel MF; Francese S; Scriven P; Carolan V; Clench MR
Anal Bioanal Chem; 2010 May; 397(2):587-601. PubMed ID: 20204332
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Protocol in Esophageal Adenocarcinoma.
Kelly P
Methods Mol Biol; 2018; 1756():281-293. PubMed ID: 29600378
[TBL] [Abstract][Full Text] [Related]
15. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
[TBL] [Abstract][Full Text] [Related]
16. MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections.
Djidja MC; Claude E; Snel MF; Scriven P; Francese S; Carolan V; Clench MR
J Proteome Res; 2009 Oct; 8(10):4876-84. PubMed ID: 19673544
[TBL] [Abstract][Full Text] [Related]
17. A new classification method for MALDI imaging mass spectrometry data acquired on formalin-fixed paraffin-embedded tissue samples.
Boskamp T; Lachmund D; Oetjen J; Cordero Hernandez Y; Trede D; Maass P; Casadonte R; Kriegsmann J; Warth A; Dienemann H; Weichert W; Kriegsmann M
Biochim Biophys Acta Proteins Proteom; 2017 Jul; 1865(7):916-926. PubMed ID: 27836618
[TBL] [Abstract][Full Text] [Related]
18. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
19. Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma.
Dekker TJ; Balluff BD; Jones EA; Schöne CD; Schmitt M; Aubele M; Kroep JR; Smit VT; Tollenaar RA; Mesker WE; Walch A; McDonnell LA
J Proteome Res; 2014 Nov; 13(11):4730-8. PubMed ID: 24762205
[TBL] [Abstract][Full Text] [Related]
20. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma.
Elsner M; Rauser S; Maier S; Schöne C; Balluff B; Meding S; Jung G; Nipp M; Sarioglu H; Maccarrone G; Aichler M; Feuchtinger A; Langer R; Jütting U; Feith M; Küster B; Ueffing M; Zitzelsberger H; Höfler H; Walch A
J Proteomics; 2012 Aug; 75(15):4693-704. PubMed ID: 22365974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
